A Mendelian randomization study investigating the causal role of inflammation on Parkinson's disease.
Humans
Mendelian Randomization Analysis
/ methods
Genome-Wide Association Study
Parkinson Disease
/ genetics
Tumor Necrosis Factor-alpha
C-Reactive Protein
/ genetics
Interleukin-6
/ genetics
Inflammation
/ genetics
Biomarkers
Receptors, Interleukin-1
/ genetics
Polymorphism, Single Nucleotide
/ genetics
Mendelian randomization
Parkinson’s disease
age at onset of Parkinson’s disease
causal inference
inflammation
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
21 10 2022
21 10 2022
Historique:
received:
17
01
2022
revised:
10
04
2022
accepted:
10
05
2022
pubmed:
4
6
2022
medline:
26
10
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
There is increasing evidence for inflammation as a determinant in the pathogenesis of Parkinson's disease, but its role in parkinsonian neurodegeneration remains elusive. It is not clear whether inflammatory cascades are causes or consequences of dopamine neuron death. In the present study, we aim to perform an in-depth statistical investigation of the causal relationship between inflammation and Parkinson's disease using a two-sample Mendelian randomization design. Genetic instruments were selected using summary-level data from the largest genome-wide association studies to date (sample size ranging from 13 955 to 204 402 individuals) conducted on a European population for the following inflammation biomarkers: C-reactive protein, interleukin-6, interleukin 1 receptor antagonist and tumour necrosis factor α. Genetic association data on Parkinson's disease (56 306 cases and 1 417 791 controls) and age at onset of Parkinson's disease (28 568 cases) were obtained from the International Parkinson's Disease Genomics Consortium. On primary analysis, causal associations were estimated on sets of strong (P-value < 5 × 10-8; F-statistic > 10) and independent (linkage disequilibrium r2 < 0.001) genetic instruments using the inverse-variance weighted method. In sensitivity analysis, we estimated causal effects using robust Mendelian randomization methods and after removing pleiotropic genetic variants. Reverse causation was also explored. We repeated the analysis on different data sources for inflammatory biomarkers to check the consistency of the findings. In all the three data sources selected for interleukin-6, we found statistical evidence for an earlier age at onset of Parkinson's disease associated with increased interleukin-6 concentration [years difference per 1 log-unit increase = -2.364, 95% confidence interval (CI) = -4.789-0.060; years difference per 1 log-unit increase = -2.011, 95% CI = -3.706 to -0.317; years difference per 1 log-unit increase = -1.569, 95% CI = -2.891 to -0.247]. We did not observe any statistical evidence for causal effects of C-reactive protein, interleukin 1 receptor antagonist and tumour necrosis factor α on both Parkinson's disease and its age at onset. Results after excluding possible pleiotropic genetic variants were consistent with findings from primary analyses. When investigating reverse causation, we did not find evidence for a causal effect of Parkinson's disease or age at onset on any biomarkers of inflammation. We found evidence for a causal association between the onset of Parkinson's disease and interleukin-6. The findings of this study suggest that the pro-inflammatory activity of the interleukin-6 cytokine could be a determinant of prodromal Parkinson's disease.
Identifiants
pubmed: 35656776
pii: 6599789
doi: 10.1093/brain/awac193
pmc: PMC9586538
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Interleukin-6
0
Biomarkers
0
Receptors, Interleukin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3444-3453Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Am J Epidemiol. 2019 Jan 1;188(1):231-238
pubmed: 30239571
Am J Hum Genet. 2018 Nov 1;103(5):691-706
pubmed: 30388399
Glia. 2016 Sep;64(9):1590-604
pubmed: 27404846
Neurosci Lett. 2020 Jan 1;714:134576
pubmed: 31654722
Nat Genet. 2015 Aug;47(8):856-60
pubmed: 26121088
JAMA Neurol. 2017 May 1;74(5):607-608
pubmed: 28288266
BMJ. 2011 Feb 15;342:d548
pubmed: 21325005
PLoS Med. 2016 Jun 21;13(6):e1001976
pubmed: 27327646
PLoS Genet. 2019 Dec 12;15(12):e1008489
pubmed: 31830040
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
Stat Med. 2021 Oct 15;40(23):5025-5045
pubmed: 34155684
Lancet Neurol. 2009 Apr;8(4):382-97
pubmed: 19296921
Front Neurosci. 2021 Feb 25;14:580311
pubmed: 33716638
Front Neurol. 2018 Dec 18;9:1081
pubmed: 30619041
Brain. 2020 Oct 1;143(10):3041-3051
pubmed: 33029617
Hum Mol Genet. 2021 Apr 27;30(5):393-409
pubmed: 33517400
Nature. 2018 Sep;561(7722):258-262
pubmed: 30135585
Int J Epidemiol. 2016 Dec 1;45(6):1717-1726
pubmed: 28338968
BMJ. 2021 Oct 26;375:n2233
pubmed: 34702754
Nat Commun. 2020 Jan 17;11(1):376
pubmed: 31953392
Neurology. 2021 Mar 23;96(12):e1672-e1679
pubmed: 33608417
Int J Epidemiol. 2003 Feb;32(1):1-22
pubmed: 12689998
Mov Disord. 2019 Jun;34(6):866-875
pubmed: 30957308
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Elife. 2018 May 30;7:
pubmed: 29846171
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
Eur J Epidemiol. 2015 Jul;30(7):543-52
pubmed: 25773750
Neurobiol Dis. 2018 Jan;109(Pt B):249-257
pubmed: 28400134
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
Int J Epidemiol. 2013 Oct;42(5):1497-501
pubmed: 24159078
NPJ Parkinsons Dis. 2021 Mar 2;7(1):17
pubmed: 33654087
Wellcome Open Res. 2021 Jan 28;6:16
pubmed: 33644404
Mov Disord. 2021 Jan;36(1):25-36
pubmed: 33314312
Am J Epidemiol. 2015 Feb 15;181(4):251-60
pubmed: 25632051
Genet Epidemiol. 2016 Nov;40(7):597-608
pubmed: 27625185
Nat Metab. 2020 Oct;2(10):1135-1148
pubmed: 33067605
Toxicol Lett. 2017 Jan 4;265:30-37
pubmed: 27865851
Nat Commun. 2021 Feb 9;12(1):886
pubmed: 33563987
Hum Mol Genet. 2014 Sep 15;23(R1):R89-98
pubmed: 25064373
J Neuroinflammation. 2018 Nov 3;15(1):305
pubmed: 30390673
Diabetes. 2014 Dec;63(12):4343-59
pubmed: 24969107
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
Econ Hum Biol. 2014 Mar;13:99-106
pubmed: 24388127
Transl Neurodegener. 2015 Oct 12;4:19
pubmed: 26464797
Front Immunol. 2021 Jul 27;12:720876
pubmed: 34386016
J Clin Neurosci. 2018 Dec;58:30-33
pubmed: 30454693
Int J Epidemiol. 2014 Jun;43(3):922-9
pubmed: 24608958
Lancet Respir Med. 2021 Jun;9(6):643-654
pubmed: 33872590
Front Neurosci. 2019 Mar 27;13:255
pubmed: 30971879
Epidemiology. 2019 Nov;30(6):813-816
pubmed: 31373921
Int J Biostat. 2016 Nov 1;12(2):
pubmed: 27092657
Lancet. 2012 Mar 31;379(9822):1205-13
pubmed: 22421339
Sci Rep. 2019 Dec 11;9(1):18911
pubmed: 31827124
Cell Immunol. 2018 May;327:77-82
pubmed: 29478949
NPJ Parkinsons Dis. 2017 Jan 11;3:3
pubmed: 28649603
Mov Disord. 2016 Jul;31(7):995-1003
pubmed: 26999434
JAMA Neurol. 2016 Nov 01;73(11):1316-1324
pubmed: 27668667